Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, multi-center, open-label, parallel group study with three arms:
- Rasburicase alone
- Rasburicase followed by Allopurinol
- Allopurinol alone
The primary objective is to compare the adequacy of control of plasma uric acid concentration
and the safety profile among the three arms.